IVVD
Get informed when a big investor buys or sells
+ FollowUndervalued by 421.2% based on the discounted cash flow analysis.
| Market cap | $284.15 Million |
|---|---|
| Enterprise Value | $132.46 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 0.71 |
| Outstanding Shares | 320,435,078 |
| P/E Ratio | -2.45 |
|---|---|
| PEG | -1.21 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.27 |
| Enterprise Value to EBIT | -1.17 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3663▼ 22.50% |
|---|---|
| Total Calls | 561,000▼ 19.97% |
| Total Puts | 205,500▼ 50.42% |
Holdings and activity of institutional investors.
| Ownership % | 73.13%▼ 66.33% |
|---|---|
| Total Invested | $294.24M▼ 50.44% |
| Investors Holding | 146▲ 25.00% |
No data
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antib...